RS55084B1 - Proces za proizvodnju metansulfonatnih soli ralfinamida ili njihovih r-enantiomera - Google Patents
Proces za proizvodnju metansulfonatnih soli ralfinamida ili njihovih r-enantiomeraInfo
- Publication number
- RS55084B1 RS55084B1 RS20160665A RSP20160665A RS55084B1 RS 55084 B1 RS55084 B1 RS 55084B1 RS 20160665 A RS20160665 A RS 20160665A RS P20160665 A RSP20160665 A RS P20160665A RS 55084 B1 RS55084 B1 RS 55084B1
- Authority
- RS
- Serbia
- Prior art keywords
- water
- salt
- methanesulfonate
- ralfinamide
- mixture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10161207 | 2010-04-27 | ||
| EP11714958.3A EP2563355B1 (en) | 2010-04-27 | 2011-04-06 | Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers |
| PCT/EP2011/055309 WO2011134763A1 (en) | 2010-04-27 | 2011-04-06 | Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS55084B1 true RS55084B1 (sr) | 2016-12-30 |
Family
ID=42634917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160665A RS55084B1 (sr) | 2010-04-27 | 2011-04-06 | Proces za proizvodnju metansulfonatnih soli ralfinamida ili njihovih r-enantiomera |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9505708B2 (enExample) |
| EP (1) | EP2563355B1 (enExample) |
| JP (3) | JP5808392B2 (enExample) |
| KR (1) | KR101851118B1 (enExample) |
| CN (2) | CN105037188B (enExample) |
| AR (1) | AR085171A1 (enExample) |
| AU (1) | AU2011246707B2 (enExample) |
| BR (1) | BR112012027623B1 (enExample) |
| CA (1) | CA2794389C (enExample) |
| CY (1) | CY1117879T1 (enExample) |
| DK (1) | DK2563355T3 (enExample) |
| EA (1) | EA021389B1 (enExample) |
| ES (1) | ES2590128T3 (enExample) |
| HR (1) | HRP20161077T1 (enExample) |
| HU (1) | HUE030504T2 (enExample) |
| IL (1) | IL222532A (enExample) |
| LT (1) | LT2563355T (enExample) |
| ME (1) | ME02509B (enExample) |
| MX (1) | MX342697B (enExample) |
| NZ (2) | NZ602648A (enExample) |
| PL (1) | PL2563355T3 (enExample) |
| PT (1) | PT2563355T (enExample) |
| RS (1) | RS55084B1 (enExample) |
| SI (1) | SI2563355T1 (enExample) |
| SM (1) | SMT201600266B (enExample) |
| TW (1) | TWI492919B (enExample) |
| WO (1) | WO2011134763A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2563355T (lt) * | 2010-04-27 | 2016-09-26 | Newron Pharmaceuticals S.P.A. | Ralfinamido metansulfonato druskų arba jų r-enentiomerų gavimo būdas |
| CN103804341B (zh) * | 2012-11-13 | 2018-04-10 | 中国人民解放军军事医学科学院毒物药物研究所 | 酰胺衍生物及其医药用途 |
| CN104761531B (zh) * | 2014-01-03 | 2017-12-01 | 中国人民解放军军事医学科学院毒物药物研究所 | 镇痛活性化合物及其医药用途 |
| CN104292128A (zh) * | 2014-07-01 | 2015-01-21 | 南京正科制药有限公司 | 一种沙芬酰胺晶型a |
| CN115368310B (zh) | 2021-05-18 | 2025-06-27 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| GB9515412D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| CN1274306C (zh) | 2001-09-03 | 2006-09-13 | 纽朗制药有限公司 | 包含加巴喷丁或其类似物和α－氨基酰胺的药物组合物及其止痛应用 |
| EP1438956A1 (en) | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
| CA2514574A1 (en) * | 2003-01-30 | 2004-08-12 | Dynogen Pharmaceuticals, Inc. | Use of sodium channel modulators for treating gastrointestinal tract disorders |
| AR044007A1 (es) | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| US20070276046A1 (en) | 2003-08-25 | 2007-11-29 | Patricia Salvati | Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents |
| EP1557166A1 (en) | 2004-01-21 | 2005-07-27 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
| EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
| RS51411B (sr) * | 2004-09-10 | 2011-02-28 | Newron Pharmaceuticals S.P.A. | Upotreba (r)-(halobenziloksi) benzilamino-propanamida kao selektivnih modulatora natrijumovih i/ili kalcijumovih kanala |
| EP1870097A1 (en) | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| KR101491541B1 (ko) * | 2006-06-19 | 2015-02-09 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 2-［4-(3- 및 2-플루오로벤질옥시)벤질아미노)프로판 아미드의 제조방법 |
| JP5315674B2 (ja) * | 2007-11-19 | 2013-10-16 | セントラル硝子株式会社 | 非水電池用電解液及びこれを用いた非水電池 |
| EP3257842B1 (en) * | 2007-12-11 | 2020-11-18 | Newron Pharmaceuticals S.p.A. | Therapeutic use of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree |
| CN101903021B (zh) | 2007-12-19 | 2012-11-14 | 纽朗制药有限公司 | 用于治疗精神病的α-氨基酰胺衍生物 |
| WO2009109334A1 (en) | 2008-03-07 | 2009-09-11 | Newron Pharmaceuticals S.P.A. | (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain |
| LT2563355T (lt) * | 2010-04-27 | 2016-09-26 | Newron Pharmaceuticals S.P.A. | Ralfinamido metansulfonato druskų arba jų r-enentiomerų gavimo būdas |
-
2011
- 2011-04-06 LT LTEP11714958.3T patent/LT2563355T/lt unknown
- 2011-04-06 HU HUE11714958A patent/HUE030504T2/en unknown
- 2011-04-06 HR HRP20161077TT patent/HRP20161077T1/hr unknown
- 2011-04-06 PT PT117149583T patent/PT2563355T/pt unknown
- 2011-04-06 JP JP2013506566A patent/JP5808392B2/ja active Active
- 2011-04-06 CN CN201510387405.XA patent/CN105037188B/zh active Active
- 2011-04-06 PL PL11714958.3T patent/PL2563355T3/pl unknown
- 2011-04-06 WO PCT/EP2011/055309 patent/WO2011134763A1/en not_active Ceased
- 2011-04-06 ES ES11714958.3T patent/ES2590128T3/es active Active
- 2011-04-06 CN CN201180020748.2A patent/CN102858330B/zh active Active
- 2011-04-06 NZ NZ602648A patent/NZ602648A/en unknown
- 2011-04-06 CA CA2794389A patent/CA2794389C/en active Active
- 2011-04-06 US US13/643,716 patent/US9505708B2/en active Active
- 2011-04-06 EA EA201291116A patent/EA021389B1/ru unknown
- 2011-04-06 NZ NZ700221A patent/NZ700221A/en unknown
- 2011-04-06 MX MX2012012093A patent/MX342697B/es active IP Right Grant
- 2011-04-06 RS RS20160665A patent/RS55084B1/sr unknown
- 2011-04-06 DK DK11714958.3T patent/DK2563355T3/en active
- 2011-04-06 AU AU2011246707A patent/AU2011246707B2/en active Active
- 2011-04-06 EP EP11714958.3A patent/EP2563355B1/en active Active
- 2011-04-06 ME MEP-2016-169A patent/ME02509B/me unknown
- 2011-04-06 KR KR1020127030931A patent/KR101851118B1/ko active Active
- 2011-04-06 BR BR112012027623-9A patent/BR112012027623B1/pt active IP Right Grant
- 2011-04-06 SI SI201130927A patent/SI2563355T1/sl unknown
- 2011-04-18 TW TW100113339A patent/TWI492919B/zh active
- 2011-04-25 AR ARP110101401A patent/AR085171A1/es not_active Application Discontinuation
-
2012
- 2012-10-18 IL IL222532A patent/IL222532A/en active IP Right Grant
-
2015
- 2015-05-22 JP JP2015104930A patent/JP6345154B2/ja active Active
-
2016
- 2016-08-05 SM SM201600266T patent/SMT201600266B/it unknown
- 2016-08-10 CY CY20161100786T patent/CY1117879T1/el unknown
- 2016-10-12 US US15/291,202 patent/US9856207B2/en active Active
-
2017
- 2017-05-30 JP JP2017106571A patent/JP6450420B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10280173B2 (en) | Ibrutinib solid forms and production process therefor | |
| JP6028016B2 (ja) | リナグリプチンベンゾエートの多形体 | |
| JP6450420B2 (ja) | ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法 | |
| CN102985090A (zh) | 5-氯-4-羟基-1-甲基-2-氧代-n-苯基-1,2-二氢喹啉-3-甲酰胺、其盐和用途 | |
| US6245917B1 (en) | Crystalline sodium phenytoin monohydrate | |
| UA124433C2 (uk) | Піридиноїлпіперидин, його застосування для лікування мігрені та фармацевтична композиція на його основі | |
| AU2011246707A1 (en) | Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers | |
| CN114195693A (zh) | 一种酰胺化合物的晶型及其制备方法 | |
| EP3569590A1 (en) | (r)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, preparation method therefor, and application thereof | |
| EP3283483B1 (en) | Crystalline eliglustat hydrochloride | |
| US10717729B2 (en) | Thiamine-organic acid salt | |
| JP2026504627A (ja) | ピリミジントリアゾール化合物の固体及び共結晶形態 | |
| JP2025528904A (ja) | Ｔｙｋ２阻害剤およびその使用 | |
| HK1213872B (en) | Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers | |
| HK1179881B (en) | Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers | |
| EA044390B1 (ru) | Полиморфы и твердые формы пиримидиниламино-пиразолового соединения и способы их получения |